Vanda’s Fanapt® Drives Growth While Regulatory Wins Signal New Opportunities for 2026
Double-Digit Fanapt® Sales Propel Overall Revenue Growth
Vanda Pharmaceuticals wrapped up 2025 with clear commercial momentum, led by a 24% increase in Fanapt® net product sales—reaching $117.3 million for the year. This performance was underpinned by a 28% gain in total prescriptions and a stunning 149% spike in new-to-brand prescriptions, highlighting accelerating adoption in treating schizophrenia and bipolar I disorder.
Total product revenues for 2025 clocked in at $216.1 million, up 9% from 2024. However, not all franchises grew: HETLIOZ® sales declined by 7% and PONVORY® saw a slight dip of 2% for the full year. The divergence underscores Fanapt®’s growing importance in Vanda’s portfolio.
| Product | 2025 Net Sales ($M) | 2024 Net Sales ($M) | % Change |
|---|---|---|---|
| Fanapt® | 117.30 | 94.30 | +24% |
| HETLIOZ® | 71.43 | 76.68 | -7% |
| PONVORY® | 27.37 | 27.80 | -2% |
| Total Revenues | 216.10 | 198.80 | +9% |
Pivotal FDA Approval and Major Pipeline Catalysts Ahead
Beyond sales, Vanda reached a milestone with the FDA approval of NEREUS™ (tradipitant), a first-in-40-years oral treatment for motion sickness. The commercial launch is set for 2026, with a parallel Phase III program in motion for GLP-1 analog-induced vomiting. The company projects this drug could address a market of 65–78 million U.S. adults—a notable runway for future growth.
Looking further out, Vanda is awaiting the February 21, 2026, FDA decision on Bysanti™ (milsaperidone) for bipolar I disorder and schizophrenia, with a Phase III study for major depressive disorder ongoing. Other advanced-stage assets include imsidolimab for generalized pustular psoriasis and VQW-765 for social anxiety disorder. These regulatory events could significantly expand the company’s commercial footprint if approvals materialize.
GAAP Net Loss Widens, Driven by Strategic Investments and One-Time Tax Charge
Financially, Vanda reported a GAAP net loss of $220.5 million for 2025, compared to $18.9 million in 2024, primarily due to a $113.7 million non-cash valuation allowance against deferred tax assets. Excluding this charge, the non-GAAP net loss would have been $106.8 million, with a diluted loss per share of $1.81. This reflects ongoing investment in R&D and commercialization efforts, as well as a sharp uptick in selling, general, and administrative expenses.
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Loss Before Taxes ($M) | 138.65 | 22.92 | ? |
| GAAP Net Loss ($M) | 220.47 | 18.90 | ? |
| Non-GAAP Net Loss ($M) | 106.78 | N/A | ? |
| Cash & Cash Equivalents ($M) | 263.80 | 374.64 | -110.84 |
The company’s cash position remains robust at $263.8 million as of year-end.
2026 Outlook: Revenue Guidance Signals Confidence in Core Portfolio
For 2026, Vanda guides to total revenues between $230 and $260 million, driven mainly by sustained Fanapt® sales ($150–$170 million expected) and stabilized contributions from HETLIOZ® and PONVORY®. Management expects a "solid baseline" from launched products, with incremental upside from new indications and product approvals. Notably, direct-to-consumer marketing and greater brand investments are anticipated to further increase Fanapt®’s market share.
| 2026 Guidance | Low End ($M) | High End ($M) |
|---|---|---|
| Total Revenues | 230 | 260 |
| Fanapt® Net Product Sales | 150 | 170 |
| Other Net Product Sales | 80 | 90 |
Strategic Takeaway: Key Decisions Ahead for Investors and Stakeholders
While 2025 saw significant operational and pipeline milestones, the widened loss owed much to a non-cash tax charge—not deteriorating business fundamentals. The high-growth trajectory for Fanapt®, the imminent launch of NEREUS™, and several pending regulatory catalysts position Vanda for another pivotal year. For investors, 2026 will turn heavily on the outcomes of Bysanti™ and imsidolimab reviews, as well as the scale of NEREUS™ uptake in a historically underserved market. The Vanda story remains one to watch for those tracking growth-stage biopharma with maturing product lines and near-term catalysts.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI